AU3895299A - Use of anti-prolactin agents to treat proliferative conditions - Google Patents

Use of anti-prolactin agents to treat proliferative conditions

Info

Publication number
AU3895299A
AU3895299A AU38952/99A AU3895299A AU3895299A AU 3895299 A AU3895299 A AU 3895299A AU 38952/99 A AU38952/99 A AU 38952/99A AU 3895299 A AU3895299 A AU 3895299A AU 3895299 A AU3895299 A AU 3895299A
Authority
AU
Australia
Prior art keywords
prolactin
proliferative conditions
treat proliferative
agents
prolactin agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38952/99A
Other languages
English (en)
Inventor
Wen Y Chen
Thomas E. Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26772335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU3895299(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of AU3895299A publication Critical patent/AU3895299A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU38952/99A 1998-05-12 1999-05-11 Use of anti-prolactin agents to treat proliferative conditions Abandoned AU3895299A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8512898P 1998-05-12 1998-05-12
US60085128 1998-05-12
US24604199A 1999-02-05 1999-02-05
US09246041 1999-02-05
PCT/US1999/010232 WO1999058142A1 (en) 1998-05-12 1999-05-11 Use of anti-prolactin agents to treat proliferative conditions

Publications (1)

Publication Number Publication Date
AU3895299A true AU3895299A (en) 1999-11-29

Family

ID=26772335

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38952/99A Abandoned AU3895299A (en) 1998-05-12 1999-05-11 Use of anti-prolactin agents to treat proliferative conditions

Country Status (11)

Country Link
US (2) US7115556B2 (enExample)
EP (2) EP1079851B1 (enExample)
JP (4) JP5259896B2 (enExample)
AT (1) ATE366114T1 (enExample)
AU (1) AU3895299A (enExample)
CA (1) CA2328520C (enExample)
DE (1) DE69936451T2 (enExample)
DK (1) DK1079851T3 (enExample)
ES (1) ES2288777T3 (enExample)
PT (1) PT1079851E (enExample)
WO (1) WO1999058142A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7201905B2 (en) 2000-03-23 2007-04-10 Greenville Hospital System Bi-functional cancer treatment agents
ES2346304T3 (es) * 2002-06-12 2010-10-14 L'oreal Composicion cosmetica de cuidado y/o maquillaje estructurada con polimeros de silicona y agentes organogelificantes, en forma rigida.
CA2509825A1 (en) 2002-12-13 2004-07-01 The Ohio State University Antagonists for human prolactin
CN102319437B (zh) 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
US8754031B2 (en) * 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
US7507716B2 (en) * 2005-07-06 2009-03-24 Board Of Regents, The University Of Texas System Method for treating pain with prolactin antagonists
WO2008028684A2 (en) * 2006-09-08 2008-03-13 Novo Nordisk A/S Peptides with high affinity for the prolactin receptor
EP2129793A1 (en) 2007-03-20 2009-12-09 Institut National De La Sante Et De La Recherche Medicale Constitutively active mutants of the prolactin receptor
WO2009003732A2 (en) * 2007-07-05 2009-01-08 Novo Nordisk A/S Peptides with high affinity for the prolactin receptor
US20110129873A1 (en) * 2008-04-30 2011-06-02 Monsanto Technology Llc Recombinant DNA Vectors for Expression of Human Prolactin Antagonists
US8648046B2 (en) 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
KR101672401B1 (ko) * 2009-02-26 2016-11-16 온코릭스, 아이엔씨. 암 줄기 세포를 가시화하고 제거하기 위한 조성물 및 방법
US8759289B2 (en) * 2010-02-03 2014-06-24 Orbis Health Solutions Llc Method for sensitizing cancer stem cells to cancer therapy
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
EP3548514A1 (en) 2016-11-29 2019-10-09 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833516A (en) * 1987-08-03 1989-05-23 International Business Machines Corporation High density memory cell structure having a vertical trench transistor self-aligned with a vertical trench capacitor and fabrication methods therefor
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
DE69231467T2 (de) 1991-05-10 2001-01-25 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden
US6429186B1 (en) 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
US5590656A (en) * 1992-09-15 1997-01-07 The Ohio State University Research Foundation Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue
DE4231297A1 (de) 1992-09-18 1994-03-24 Basf Ag Verfahren zur Herstellung von 3-(2'-Oxyethyl)-dihydro-2-(3H)furanonen
JP3983280B2 (ja) * 1993-02-19 2007-09-26 ジェネンテック・インコーポレーテッド 乳ガンの治療のためのリガンドアンタゴニスト
CN1053658C (zh) * 1994-04-06 2000-06-21 日本新药株式会社 氨基芪唑衍生物和药
DE19718721C2 (de) * 1997-05-02 1999-10-07 Siemens Ag DRAM-Zellenanordnung und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
DK1079851T3 (da) 2007-09-24
JP2011079821A (ja) 2011-04-21
CA2328520A1 (en) 1999-11-18
WO1999058142A1 (en) 1999-11-18
ATE366114T1 (de) 2007-07-15
US7115556B2 (en) 2006-10-03
JP5453355B2 (ja) 2014-03-26
CA2328520C (en) 2013-06-25
DE69936451T2 (de) 2008-03-13
JP2002515404A (ja) 2002-05-28
PT1079851E (pt) 2007-10-08
EP1079851B1 (en) 2007-07-04
JP2013224309A (ja) 2013-10-31
US20030022833A1 (en) 2003-01-30
WO1999058142A9 (en) 2000-02-10
ES2288777T3 (es) 2008-01-16
EP2316467A1 (en) 2011-05-04
DE69936451D1 (de) 2007-08-16
EP1079851A4 (en) 2004-03-17
JP2012020996A (ja) 2012-02-02
US20070060520A1 (en) 2007-03-15
EP1079851A1 (en) 2001-03-07
JP5259896B2 (ja) 2013-08-07

Similar Documents

Publication Publication Date Title
IL146482A0 (en) Tek antagonists
DK1079851T3 (da) Anvendelse af anti-prolactinmidler til behandling af cancer
AP1869A (en) b2- Adrenergic receptor agonists.
WO2001045730A3 (en) Tweak receptor
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
PT1955700E (pt) Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
YU42302A (sh) Agonisti beta2-adrenergičnih receptora
PL330496A1 (en) Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy
HK1038755A1 (zh) Tweak及tweak受体对抗物和使用对抗物治疗免疫失常症
SI1556058T1 (sl) Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
YU20600A (sh) Nova upotreba antagonista 5-ht3 receptora
CZ2000531A3 (en) Method of prevention or therapy of estrogen-dependent diseases and disorders
NZ329627A (en) 8-Heterocyclically substituted 1,3,8-triaza-spiro[4.5]decan-4-ones
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
IL139591A0 (en) Combination therapy for treatment of bipolar disorders
ZA200004260B (en) Treatment of skin disorders.
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
CA2245766A1 (en) Compositions useful in the phototherapeutic treatment of proliferative skin disorders
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
EP1108426A3 (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
WO2001015677A3 (en) Use of 5-ht1b/1d agonists to treat otic pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase